• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现一种双重 WDR5 和 Ikaros PROTAC 降解剂作为抗癌治疗药物。

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.

机构信息

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

出版信息

Oncogene. 2022 Jun;41(24):3328-3340. doi: 10.1038/s41388-022-02340-8. Epub 2022 May 7.

DOI:10.1038/s41388-022-02340-8
PMID:35525905
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9189076/
Abstract

WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine methyltransferase complex, is critically involved in oncogenesis and represents an attractive onco-target. Inhibitors targeting protein-protein interactions (PPIs) between WDR5 and its binding partners, however, do not inhibit all of WDR5-mediated oncogenic functions and exert rather limited antitumor effects. Here, we report a cereblon (CRBN)-recruiting proteolysis targeting chimera (PROTAC) of WDR5, MS40, which selectively degrades WDR5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40-induced WDR5 degradation caused disassociation of the MLL/KMT2A complex off chromatin, resulting in decreased H3K4me2. Transcriptomic profiling revealed that targets of both WDR5 and IMiDs:CRBN were significantly repressed by treatment of MS40. In MLL-rearranged leukemias, which exhibit IKZF1 high expression and dependency, co-suppression of WDR5 and Ikaros by MS40 is superior in suppressing oncogenesis to the WDR5 PPI inhibitor, to MS40's non-PROTAC analog controls (MS40N1 and MS40N2, which do not bind CRBN and WDR5, respectively), and to a matched VHL-based WDR5 PROTAC (MS169, which degrades WDR5 but not Ikaros). MS40 suppressed the growth of primary leukemia patient cells in vitro and patient-derived xenografts in vivo. Thus, dual degradation of WDR5 and Ikaros is a promising anti-cancer strategy.

摘要

WD 重复结构域 5(WDR5)是 MLL/KMT2A 赖氨酸甲基转移酶复合物的一个组成部分,在肿瘤发生中起着至关重要的作用,是一个有吸引力的癌靶点。然而,靶向 WDR5 与其结合伙伴之间蛋白-蛋白相互作用(PPIs)的抑制剂并不能抑制所有 WDR5 介导的致癌功能,并且只发挥了相当有限的抗肿瘤作用。在这里,我们报告了 WDR5 的一个 cereblon(CRBN)募集蛋白水解靶向嵌合体(PROTAC)MS40,它可以选择性地降解 WDR5 和免疫调节药物(IMiDs)的既定新底物:CRBN、Ikaros 锌指(IKZF)转录因子 IKZF1 和 IKZF3。MS40 诱导的 WDR5 降解导致 MLL/KMT2A 复合物从染色质上解离,导致 H3K4me2 减少。转录组分析显示,WDR5 和 IMiDs:CRBN 的靶标都被 MS40 的处理显著抑制。在 MLL 重排的白血病中,IKZF1 高表达和依赖性,MS40 对 WDR5 和 Ikaros 的共同抑制在抑制肿瘤发生方面优于 WDR5 PPI 抑制剂、MS40 的非 PROTAC 对照(MS40N1 和 MS40N2,分别不与 CRBN 和 WDR5 结合),以及匹配的基于 VHL 的 WDR5 PROTAC(MS169,降解 WDR5 但不降解 Ikaros)。MS40 抑制了体外原代白血病患者细胞和体内患者来源异种移植瘤的生长。因此,WDR5 和 Ikaros 的双重降解是一种很有前途的抗癌策略。

相似文献

1
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.发现一种双重 WDR5 和 Ikaros PROTAC 降解剂作为抗癌治疗药物。
Oncogene. 2022 Jun;41(24):3328-3340. doi: 10.1038/s41388-022-02340-8. Epub 2022 May 7.
2
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.cereblon 无序区域是通过蛋白水解靶向嵌合体进行有效降解所必需的。
Sci Rep. 2019 Dec 23;9(1):19654. doi: 10.1038/s41598-019-56177-5.
3
Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer.发现强效且选择性的靶向WDR5蛋白水解嵌合体作为胰腺癌的潜在治疗药物
J Med Chem. 2023 Dec 14;66(23):16168-16186. doi: 10.1021/acs.jmedchem.3c01521. Epub 2023 Nov 29.
4
Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.发现首例核受体结合 SET 域蛋白 2(NSD2)和 Ikaros/Aiolos 的降解剂。
J Med Chem. 2022 Aug 11;65(15):10611-10625. doi: 10.1021/acs.jmedchem.2c00807. Epub 2022 Jul 27.
5
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).免疫调节剂来那度胺和泊马度胺通过调节 E3 泛素连接酶复合物 CRL4(CRBN),诱导 T 细胞抑制因子 Ikaros 和 Aiolos 的降解,从而共同刺激 T 细胞。
Br J Haematol. 2014 Mar;164(6):811-21. doi: 10.1111/bjh.12708. Epub 2013 Dec 13.
6
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.一种选择性的 WDR5 降解剂可抑制患者来源的小鼠模型中的急性髓系白血病。
Sci Transl Med. 2021 Sep 29;13(613):eabj1578. doi: 10.1126/scitranslmed.abj1578.
7
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.基于泊马度胺的同型PROTAC对E3泛素连接酶大脑神经酰胺酶的化学失活作用
J Vis Exp. 2019 May 15(147). doi: 10.3791/59472.
8
Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.质子泵抑制剂通过破坏 MLL1-WDR5 蛋白-蛋白相互作用,选择性地抑制 MLL 重排白血病细胞。
Eur J Med Chem. 2020 Feb 15;188:112027. doi: 10.1016/j.ejmech.2019.112027. Epub 2019 Dec 31.
9
A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.在骨髓瘤细胞中进行的全基因组 CRISPR-Cas9 筛选鉴定了免疫调节药物敏感性的调节剂。
Leukemia. 2019 Jan;33(1):171-180. doi: 10.1038/s41375-018-0205-y. Epub 2018 Jul 19.
10
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation.通过多种新底物降解,新型强效分子胶降解剂针对广泛的血液癌细胞系。
J Hematol Oncol. 2024 Sep 2;17(1):77. doi: 10.1186/s13045-024-01592-z.

引用本文的文献

1
Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.TP53基因发生突变、单核苷酸多态性及野生型的骨髓增生异常综合征/急性髓系白血病患者的预后比较及预后因素分析
Hum Genomics. 2025 Aug 28;19(1):98. doi: 10.1186/s40246-025-00792-z.
2
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics.通过高通量蛋白质组学对cereblon新底物图谱进行无偏映射。
Nat Commun. 2025 Aug 20;16(1):7773. doi: 10.1038/s41467-025-62829-0.
3
Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies.急性髓系白血病中KMT2A重排的见解:从分子特征到靶向治疗
Biomark Res. 2025 May 13;13(1):73. doi: 10.1186/s40364-025-00786-y.
4
Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma.WDR5的药理学降解可抑制SS18::SSX的致癌活性,并为滑膜肉瘤提供一种治疗方法。
Sci Adv. 2025 Apr 25;11(17):eads7876. doi: 10.1126/sciadv.ads7876. Epub 2025 Apr 23.
5
Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.DCAF1-PROTAC-WDR5 三元复合物的晶体结构为 DCAF1 底物特异性提供了深入了解。
Nat Commun. 2024 Nov 23;15(1):10165. doi: 10.1038/s41467-024-54500-x.
6
Histone methyltransferase KMT2A: Developmental regulation to oncogenic transformation.组蛋白甲基转移酶 KMT2A:从发育调控到致癌转化。
J Biol Chem. 2024 Oct;300(10):107791. doi: 10.1016/j.jbc.2024.107791. Epub 2024 Sep 18.
7
The Wild West of spike-in normalization.掺入标准化的蛮荒西部。
Nat Biotechnol. 2024 Sep;42(9):1343-1349. doi: 10.1038/s41587-024-02377-y.
8
Initial Characterization of WDR5B Reveals a Role in the Proliferation of Retinal Pigment Epithelial Cells.WDR5B 的初步特征分析表明其在视网膜色素上皮细胞增殖中的作用。
Cells. 2024 Jul 13;13(14):1189. doi: 10.3390/cells13141189.
9
Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.核糖体亚基耗竭和 p53-MDM4 轴的激活主导了 MLL 重排癌细胞对 WDR5 WIN 位点抑制的反应。
Elife. 2024 Apr 29;12:RP90683. doi: 10.7554/eLife.90683.
10
Luciferase- and HaloTag-based reporter assays to measure small-molecule-induced degradation pathway in living cells.基于荧光素酶和 HaloTag 的报告基因检测法,用于测量小分子诱导的活细胞降解途径。
Nat Protoc. 2024 Aug;19(8):2317-2357. doi: 10.1038/s41596-024-00979-z. Epub 2024 Apr 18.

本文引用的文献

1
Ikaros Proteins in Tumor: Current Perspectives and New Developments.肿瘤中的Ikaros蛋白:当前观点与新进展
Front Mol Biosci. 2021 Dec 7;8:788440. doi: 10.3389/fmolb.2021.788440. eCollection 2021.
2
Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q.来那度胺在不依赖5号染色体长臂缺失的髓系恶性肿瘤中的新型分子机制
Cancers (Basel). 2021 Oct 11;13(20):5084. doi: 10.3390/cancers13205084.
3
A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models.一种选择性的 WDR5 降解剂可抑制患者来源的小鼠模型中的急性髓系白血病。
Sci Transl Med. 2021 Sep 29;13(613):eabj1578. doi: 10.1126/scitranslmed.abj1578.
4
Phase separation drives aberrant chromatin looping and cancer development.相分离驱动染色质异常环化和癌症发生。
Nature. 2021 Jul;595(7868):591-595. doi: 10.1038/s41586-021-03662-5. Epub 2021 Jun 23.
5
Advancing targeted protein degradation for cancer therapy.推进靶向蛋白降解治疗癌症。
Nat Rev Cancer. 2021 Oct;21(10):638-654. doi: 10.1038/s41568-021-00365-x. Epub 2021 Jun 15.
6
The language of chromatin modification in human cancers.人类癌症中染色质修饰的语言。
Nat Rev Cancer. 2021 Jul;21(7):413-430. doi: 10.1038/s41568-021-00357-x. Epub 2021 May 17.
7
Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders.WD-重复蛋白 5(WDR5)降解剂的设计、合成与评价。
J Med Chem. 2021 Aug 12;64(15):10682-10710. doi: 10.1021/acs.jmedchem.1c00146. Epub 2021 May 13.
8
ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism.ZMYND11-MBTD1 通过劫持 NuA4/TIP60 乙酰转移酶复合物和 PWWP 介导的染色质关联机制诱导白血病发生。
Nat Commun. 2021 Feb 16;12(1):1045. doi: 10.1038/s41467-021-21357-3.
9
BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis.BAHCC1 通过一个保守的 BAH 模块结合 H3K27me3 来介导基因沉默和致癌作用。
Nat Genet. 2020 Dec;52(12):1384-1396. doi: 10.1038/s41588-020-00729-3. Epub 2020 Nov 2.
10
Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.新型双靶点EZH2/HDAC抑制剂的设计:癌细胞中的生化活性及生物学评价
ACS Med Chem Lett. 2020 Mar 19;11(5):977-983. doi: 10.1021/acsmedchemlett.0c00014. eCollection 2020 May 14.